Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).

Pieter Sonneveld,Annemiek Broijl,Mario Boccadoro,Hermann Einsele,Joan Bladé,Meletios A. Dimopoulos,Michel Delforge,Andrew Spencer,Roman Hájek,Fredrik H. Schjesvold,Sarah Lonergan,Elena Smith,Robin Carson,Wendy Crist,Wendy S. Garvin,Jessica Vermeulen,Philippe Moreau

Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS).

2019

Pieter Sonneveld
Annemiek Broijl
Mario Boccadoro
Hermann Einsele
Joan Bladé
Meletios A. Dimopoulos
Michel Delforge
Andrew Spencer
Roman Hájek
Fredrik H. Schjesvold
Sarah Lonergan
Elena Smith
Robin Carson
Wendy Crist
Wendy S. Garvin
Jessica Vermeulen
Philippe Moreau

TPS8055Background: DARA, a human, CD38-targeting, IgGκ monoclonal antibody, is approved in many countries for use as monotherapy in relapsed/refractory MM (RRMM), and in combination with standard-o...

Keywords:

Daratumumab
Oncology
Pathology
Dexamethasone
Monoclonal antibody
Refractory
Internal medicine
Dara
Medicine
Multiple myeloma
Bortezomib/lenalidomide
in patient
newly diagnosed

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations